What Are Wall Street Analysts' Target Price for Hologic Stock?
/Hologic%2C%20Inc_%20%20magnified%20-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Marlborough, Massachusetts-based Hologic, Inc. (HOLX) develops, manufactures, and supplies diagnostic products, imaging systems, and surgical products for women's health, helping in the early detection and treatment of diseases worldwide. With a market cap of $15.1 billion, Hologic operates through Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments.
The company has significantly underperformed the broader market over the past year. HOLX stock has declined 15.4% over the past 52 weeks and 4.3% on a YTD basis, lagging behind the S&P 500 Index’s ($SPX) 19% surge over the past year and 10% returns in 2025.
Narrowing the focus, Hologic has also underperformed the industry-focused iShares U.S. Medical Devices ETF’s (IHI) 10.3% gains over the past 52 weeks and 5.9% returns in 2025.
While Hologic has underperformed the broader market over the past year, it has observed significant gains in recent months. Its stock prices have shot up more than 20% in the past three months alone. Further, HOLX stock gained 2.8% in the trading session following the release of its better-than-expected Q3 results on Jul. 30. The company’s topline for the quarter inch up 1.2% year-over-year to $1.02 billion, surpassing the consensus estimates by 1.7%. Moreover, its adjusted EPS grew by 1.9% to $1.08, coming ahead of the management's guidance range and beating the Street’s expectations by 2.9%.
For the full fiscal 2025, ending in September, analysts expect Hologic to deliver an adjusted EPS of $4.24, up 3.9% year-over-year. The company has a mixed earnings surprise history. While it missed the Street’s bottom-line estimates once over the past four quarters, it surpassed the projections on three other occasions.
The stock has a consensus “Moderate Buy” rating overall. Of the 19 analysts covering the stock, opinions include six “Strong Buys,” two “Moderate Buys,” and 11 “Holds.”
This configuration is slightly more optimistic than two months ago, when five analysts gave “Strong Buy” recommendations and only one analyst suggested a “Moderate Buy” rating.
On Aug. 6, RBC Capital analyst Conor McNamara upgraded HOLX from “Sector Perform” to “Outperform” and raised the price target from $72 to $87.
As of writing, Hologic’s mean price target of $73 suggests a modest 5.8% upside potential from current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.